News
TTRX
6.85
+0.44%
0.03
Weekly Report: what happened at TTRX last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at TTRX last week (0608-0612)?
Weekly Report · 06/15 10:42
Weekly Report: what happened at TTRX last week (0601-0605)?
Weekly Report · 06/08 10:37
Turn Therapeutics Highlights GX-03 Phase 2 Atopic Dermatitis Data
TipRanks · 06/03 10:35
Turn Therapeutics Reports Interim Phase 2 GX-03 Data In Atopic Dermatitis; Stock Up
NASDAQ · 06/02 09:54
Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch
NASDAQ · 06/02 03:07
Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results
Dow Jones · 06/01 18:30
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 06/01 17:06
Turn announces interim analysis findings from Phase 2 trial of GX-03
TipRanks · 06/01 14:54
Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data
TipRanks · 06/01 13:46
Turn Therapeutics Announces Interim Analysis Findings From First 50 Completed Subjects Enrolled In Ongoing Randomized, Double-Blind, Vehicle-Controlled Phase 2 Clinical Trial Evaluating GX-03 In Adults With Atopic Dermatitis
Benzinga · 06/01 12:36
Turn Therapeutics says Phase 2 interim data show GX-03 hits 70.4% EASI-75 at week 4 in atopic dermatitis trial
PUBT · 06/01 12:30
TURN THERAPEUTICS - INTERIM ANALYSIS LEADS TO TRIAL ENROLLMENT AND ENDPOINT REFINEMENT
Reuters · 06/01 12:30
TURN THERAPEUTICS REPORTS INTERIM ANALYSIS FINDINGS AND ADAPTIVE OPTIMIZATION STRATEGY FROM PHASE 2 GX-03 TRIAL IN MODERATE-TO-SEVERE ATOPIC DERMATITIS
Reuters · 06/01 12:30
Weekly Report: what happened at TTRX last week (0525-0529)?
Weekly Report · 06/01 10:43
Turn Therapeutics announces peer-reviewed article on GX-03
TipRanks · 05/27 14:27
Turn Therapeutics highlights GX-03 preclinical data in dermatitis
TipRanks · 05/27 12:29
Turn Therapeutics reports GX-03 cuts disease severity in IL-36 murine dermatitis study published in Journal of Dermatological Treatment
PUBT · 05/27 12:07
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
Barchart · 05/27 07:05
Weekly Report: what happened at TTRX last week (0518-0522)?
Weekly Report · 05/25 10:47
More
Webull provides a variety of real-time TTRX stock news. You can receive the latest news about Turn Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TTRX
Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.